USCOM LIMITED — Regulatory Filings 2009

Dec 20, 2009

Uscom Limited ABN 35091028090 Suite 1, Level 7, 10 Loftus Street Sydney NSW 2000 Australia T +612 9247 4144 F +612 9247 8157 www.uscom.com.au

M A R K E T A N N O U N C E M E N T

USCOM – Presented at Rome Congress and European Users Meeting

Monday 21st December 2009: Uscom (ASX code: UCM) today announced the presentation of new research by Assoc. Prof. Brendan Smith of Australia demonstrating remarkably positive results for management of septic shock using USCOM at the International Haemodynamics Monitoring Update in Rome, Italy. This followed a meeting of invited European and Australian experts in circulation at St Thomas’ Hospital London, which was convened to review current USCOM science and advance its routine use in worldwide critical care practice.

The Update on Haemodynamic Monitoring meeting held in Rome, Italy, on Monday 14[th] December, was attended by 229 critical care experts from 37 countries and focused on future trends in haemodynamic monitoring and management. Assoc. Prof. Brendan Smith presented results from his USCOM based management of sepsis and heart failure. Prof Smith is an early adopter of USCOM and has developed innovative treatments which are demonstrating exciting improvements in outcomes of sepsis patients. Sepsis is a serious infective disease which kills many adults and children worldwide each year and has become the subject of co-ordinated global efforts to improve survival from the disease.

The high level meeting in London was chaired by Professor David Bennett at St Thomas’ Hospital in London and was attended by 10 invited Professors and 20 clinical researchers from Europe and Australia and was focussed on evaluating current clinical uses of USCOM and the development of future applications. An outcome of the meeting was the planning of a number of multi-centre trials in heart failure, sepsis, and liver transplantation in adults and children in major critical care centres across Europe and Australia.

Mr Paul Butler, the Uscom CEO said “These meetings involved current clinical users of USCOM and represents the first co-ordinated steps to introduce USCOM into widespread clinical use in Europe. This activity coincides with Spacelabs launch of USCOM in Europe and will provide invaluable support for the Spacelabs European sales team.”

Rob Phillips, the Executive Chairman of Uscom and Director of Clinical Science said “This focus on USCOM by such influential critical care thinkers represents another significant step in the global recognition of USCOM as a standard tool in critical care and will result in the multi-centre studies required to ensure widespread clinical application of USCOM.”

About Uscom

Uscom Limited is an Australian medical device company which was first listed on the Australian Stock Exchange in December 2003. Uscom has developed a Non Invasive Cardiac Output Monitor. The USCOM is a simple, cost-effective and non-invasive device that measures heart function, detects irregularities and guides treatment. The USCOM device has major applications in Paediatrics, Emergency Medicine, Intensive Care Units and Anesthesia, and is a tool of choice for management of adult and paediatric sepsis, and for the guidance of all fluid administration.

USCOM has global regulatory approval and the technology is currently marketed in North America, South America, Europe, the Middle East, India and Australia by Spacelabs Healthcare, while in China and SE Asia USCOM is distributed by Pacific Medical Systems and in New Zealand it is distributed by MedXus.

Uscom Contacts

Paul Butler Rob Phillips Chief Executive Officer Executive Chairman paul.butler@uscom.com.au rob@uscom.com.au